Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0043346 (
xeroderma pigmentosum
)
2,924
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
MAD2
(mitotic arrest deficient 2) is a key regulator of mitosis. Recently, it had been suggested that
MAD2
-induced mitotic arrest mediates DNA damage response and that upregulation of
MAD2
confers sensitivity to DNA-damaging anticancer drug-induced apoptosis. In this study, we report a potential novel role of
MAD2
in mediating DNA nucleotide excision repair through physical interactions with two DNA repair proteins, XPD (
xeroderma pigmentosum
complementation group D) and ERCC1. First, overexpression of
MAD2
resulted in decreased nuclear accumulation of XPD, a crucial step in the initiation of DNA repair. Second, immunoprecipitation experiments showed that
MAD2
was able to bind to XPD, which led to competitive suppression of binding activity between XPD and XPA, resulting in the prevention of physical interactions between DNA repair proteins. Third, unlike its role in mitosis, the N-terminus domain seemed to be more important in the binding activity between
MAD2
and XPD. Fourth, phosphorylation of H2AX, a process that is important for recruitment of DNA repair factors to DNA double-strand breaks, was suppressed in
MAD2
-overexpressing cells in response to DNA damage. These results suggest a negative role of
MAD2
in DNA damage response, which may be accounted for its previously reported role in promoting sensitivity to DNA-damaging agents in cancer cells. However, the interaction between
MAD2
and ERCC1 did not show any effect on the binding activity between ERCC1 and XPA in the presence or absence of DNA damage. Our results suggest a novel function of
MAD2
by interfering with DNA repair proteins.
...
PMID:MAD2 interacts with DNA repair proteins and negatively regulates DNA damage repair. 1859 77